Showing results (821-830 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 7, 2012
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanomaPatrick A Ott, Richard D Carvajal, Neeta Pandit-Taskar, et al.
Investigational New Drugs|August 11, 2012
Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitorAnne-Sophie Belzacq-Casagrande, Florence Bachelot, Catherine De Oliveira, et al.
Investigational New Drugs|August 9, 2020
Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivoTao Song, Mingyu Zhang, Jun Wu, et al.
Investigational New Drugs|July 12, 2020
Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case reportMegumu Osaki, Ryo Tachikawa, Junichiro Ohira, et al.
Investigational New Drugs|August 10, 2020
B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cellsXin Sun, Jingyuan Zhao, Li Ma, et al.
Investigational New Drugs|June 12, 2014
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumorsJames M Cleary, Caio Max S Rocha Lima, Herbert I Hurwitz, et al.
Investigational New Drugs|June 13, 2014
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineLawrence M Gelbert, Shufen Cai, Xi Lin, et al.
Investigational New Drugs|January 25, 2014
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsMargaret von Mehren, Carolyn D Britten, Peter Pieslor, et al.
Investigational New Drugs|May 16, 2014
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginaseWei-Wen Chien, Soraya Allas, Nicolas Rachinel, et al.
Investigational New Drugs|January 21, 2014
Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literatureAngus Dalgleish, Peter Featherstone, Viatcheslav Vlassov, et al.
Pageof 372